Assembly Biosciences (ASMB) and Its Rivals Head to Head Analysis

Assembly Biosciences (NASDAQ: ASMB) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Assembly Biosciences to related companies based on the strength of its institutional ownership, analyst recommendations, earnings, dividends, profitability, risk and valuation.

Risk & Volatility

Assembly Biosciences has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Assembly Biosciences’ peers have a beta of 0.85, suggesting that their average share price is 15% less volatile than the S&P 500.

Profitability

This table compares Assembly Biosciences and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Assembly Biosciences N/A -68.83% -43.63%
Assembly Biosciences Competitors -538.85% -41.85% -24.81%

Valuation and Earnings

This table compares Assembly Biosciences and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Assembly Biosciences $3.04 million -$50.92 million -12.89
Assembly Biosciences Competitors $2.57 billion $977.16 million 0.71

Assembly Biosciences’ peers have higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings for Assembly Biosciences and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Assembly Biosciences 0 0 1 0 3.00
Assembly Biosciences Competitors 63 294 946 27 2.70

Assembly Biosciences currently has a consensus target price of $35.00, suggesting a potential downside of 0.88%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 17.28%. Given Assembly Biosciences’ peers higher possible upside, analysts plainly believe Assembly Biosciences has less favorable growth aspects than its peers.

Insider & Institutional Ownership

72.3% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 66.4% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by institutional investors. 19.6% of Assembly Biosciences shares are owned by insiders. Comparatively, 10.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Assembly Biosciences peers beat Assembly Biosciences on 7 of the 12 factors compared.

About Assembly Biosciences

Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.

Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply